Holen Sie sich die Stockscreener-App
1.75
0.57%
-0.01
Handel nachbörslich:
1.77
0.02
+1.14%
Schlusskurs vom Vortag:
$1.76
Offen:
$1.75
24-Stunden-Volumen:
71,500
Relative Volume:
0.78
Marktkapitalisierung:
$37.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.94M
KGV:
-0.6162
EPS:
-2.84
Netto-Cashflow:
$-13.83M
1W Leistung:
-22.57%
1M Leistung:
-36.59%
6M Leistung:
-42.43%
1J Leistung:
-43.55%
1-Tages-Spanne:
$1.70
$1.88
1-Wochen-Bereich:
$1.70
$2.35
52-Wochen-Spanne:
$1.61
$7.42
Aileron Therapeutics Inc Stock (ALRN) Company Profile
Firmenname
Aileron Therapeutics Inc
Sektor
Branche
Telefon
(737) 802-1989
Adresse
12407 N. MOPAC EXPY., AUSTIN, MA
Vergleichen Sie ALRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALRN
Aileron Therapeutics Inc
|
1.75 | 37.92M | 0 | -12.94M | -13.83M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-07-24 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-24 | Eingeleitet | Jefferies | Buy |
| 2017-07-24 | Eingeleitet | William Blair | Outperform |
Aileron Therapeutics Inc Aktie (ALRN) Neueste Nachrichten
Aileron Therapeutics to Present at the 8th Annual IPF Summit - The Eastern Progress Online
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock By Investing.com - Investing.com Nigeria
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock - Investing.com
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - The Eastern Progress Online
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat
Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy
Aileron Reports Positive Phase 1b Data for IPF Drug, Shows Strong Biomarker Response | ALRN Stock News - StockTitan
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - AOL
Aileron reports promising phase 1b trial results for IPF treatment - Investing.com
Aileron reports promising phase 1b trial results for IPF treatment By Investing.com - Investing.com UK
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq
Advancium explores ALRN-6924 for pediatric eye cancer treatment - Investing.com India
Advancium explores ALRN-6924 for pediatric eye cancer treatment By Investing.com - Investing.com Canada
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PR Newswire
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat
Constrained Peptide Drugs Market Size, Scope and Share Analysis - InsightAce Analytic
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat
ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard
University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat
Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat
Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily
Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Keith Johns Joins Allurion's Board Of Directors - MPO-mag
HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer
Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg
Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World
1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat
Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle
Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex
Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device
Finanzdaten der Aileron Therapeutics Inc-Aktie (ALRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aileron Therapeutics Inc-Aktie (ALRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 17 '24 |
Sale |
3.25 |
4,707 |
15,298 |
1,746,549 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 14 '24 |
Sale |
3.30 |
1,900 |
6,270 |
1,751,256 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 10 '24 |
Sale |
3.30 |
9,577 |
31,604 |
1,768,250 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 12 '24 |
Sale |
3.25 |
9,342 |
30,362 |
1,753,156 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 11 '24 |
Sale |
3.26 |
5,752 |
18,744 |
1,762,498 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 05 '24 |
Sale |
3.30 |
6,291 |
20,760 |
1,783,851 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 06 '24 |
Sale |
3.29 |
4,284 |
14,104 |
1,779,567 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 07 '24 |
Sale |
3.26 |
1,740 |
5,664 |
1,777,827 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
May 01 '24 |
Sale |
4.21 |
20,315 |
85,473 |
1,779,306 |
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Apr 29 '24 |
Sale |
4.95 |
10,746 |
53,182 |
1,799,711 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):